NORD's Living Rare Study Aims to Transform Rare Disease Understanding
NORD's Living Rare Study Aims to Transform Rare Disease Understanding
This initiative will enhance policy and resource allocation
Today, the National Organization for Rare Disorders (NORD) unveiled the Living Rare Study, a revolutionary initiative aimed at understanding the full range of challenges faced by individuals living with rare diseases. As the first extensive study of its kind, it seeks to shed light on the unique hurdles encountered by patients and their caregivers, helping to improve access to healthcare and vital resources.
"Rare diseases impact over 30 million Americans, representing a significant public health concern. However, the absence of comprehensive data has obscured their impact," stated Pamela Gavin, the CEO of NORD. The Living Rare Study is set to remedy this situation by collecting firsthand experiences from those affected, thus providing essential insights for advocating improvements in healthcare policy.
This study, developed with feedback from patients and caregivers, will delve into various facets of living with a rare disease, such as healthcare accessibility, emotional challenges, and financial strains faced by families. By exploring important factors like geography and access to treatment, it aims to illuminate how these variables can influence health outcomes for rare disease patients.
"For the first time, we will gather extensive data not just on medical difficulties but also on the wider social and economic implications of rare diseases," remarked Edward Neilan, M.D., Ph.D., Chief Medical and Scientific Officer of NORD. He emphasized that such insights are critical for improving the management of rare diseases and promoting equitable health care access.
NORD intends to leverage the data gleaned from this study to highlight pressing issues, shape future initiatives, and educate both the public and policymakers about the existing challenges faced by the rare disease community. They plan to regularly publish reports that analyze these factors and inform resource allocation at both local and national levels.
The Living Rare Study welcomes participation from anyone diagnosed with a rare disease, as well as their caregivers, who can offer a critical perspective on the research. The survey is designed to be user-friendly and adaptable, allowing individuals to participate at their convenience and update their insights annually. Participants will have the opportunity to compare their responses with those of others, making the findings even more impactful. All data will be securely stored on NORD's IAMRARE platform, which adheres to HIPAA standards, ensuring participant confidentiality.
“Living with a rare disease creates interconnected challenges that affect all aspects of life, including finances and emotional well-being,” commented Gavin. “By increasing participation in the study, we can gather more powerful data to advocate for changes that will benefit the rare disease community significantly.”
Learn more about the Living Rare Study and how to get involved by visiting livingrarestudy.org.
About the National Organization for Rare Disorders (NORD)
With over 40 years of dedication to advancing care and treatment for individuals with rare diseases, the National Organization for Rare Disorders (NORD) stands as a leading voice for the approximately 30 million Americans navigating these health challenges. Operating as an independent nonprofit, NORD champions individuals with rare diseases and the groups that support them. Partnering with over 340 patient organizations, their mission is to improve health outcomes by driving advancements in care, research, and policy.
Frequently Asked Questions
What is the Living Rare Study?
The Living Rare Study is a comprehensive research initiative by NORD aimed at gathering data on the challenges faced by individuals living with rare diseases.
Who can participate in the Living Rare Study?
Anyone diagnosed with a rare disease, as well as their caregivers, are encouraged to participate in the study.
How will the findings of the study be used?
NORD will use the findings to inform advocacy efforts, shape programs, and educate the public and lawmakers on the challenges of living with rare diseases.
What type of data will be collected?
The study will collect data on medical challenges, healthcare access, emotional well-being, and financial burdens associated with living with a rare disease.
How does NORD ensure participant privacy?
All data collected will be securely stored on NORD's IAMRARE platform, which is fully compliant with HIPAA regulations to protect participant privacy.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Insights into Denny's Upcoming Earnings Announcement
- Controladora Vuela Earnings Preview: What Investors Expect
- Investors Anticipate PennyMac Mortgage's Upcoming Earnings Report
- TruBridge Welcomes Amy O'Keefe to Board of Directors Team
- Investor Optimism Growing in U.S. Fixed Income Market
- Puma Exploration Advances Acquisition of Key Mining Claims
- Understanding Hershey's Price-to-Earnings Dynamics Today
- QRTEB Stock Hits 52-Week Low: Insights and Future Outlook
- Mexico's Inflation Trends: Key Insights for October Forecasts
- Key Economic Indicators and Fed Insights to Watch
Recent Articles
- PPG Industries Adjusts Targets Amid Auto Industry Shifts
- UBS Analyzes China's Stimulus: Small Steps for Big Impact
- Cold Sore Treatment Market: Growth to $1.57 Billion by 2031
- Motiff Launches Advanced Multimodal Language Models
- Emirates Airlines Boosts Cargo Operations with New Freighters
- Anna Gullmarstrand Takes on CFO Role at New Wave Group
- Edesa Biotech Announces Conference Engagements and Insights
- Celebrating Community Resilience at Harvest Nights Music Festival
- Tristel Sees Exceptional Growth with Record Revenues and Profits
- Loomis to Release Financial Report and Capital Markets Day
- Ocean Power Technologies Partners with Remah Group for Growth
- What the Future Holds for Waymo and Tesla Without Ridesharing
- Experience the Latest Innovations from NEWTON GOLF at LD Micro
- Challenges Faced by Shell in Asset Sale to Renaissance Group
- Phunware's Upcoming Presentation Highlighting Innovations
- Political Uncertainty Fuels Gold Surge and Dollar Strength
- 5E Advanced Materials Takes Big Steps with Lithium Capex and Tax Benefits
- Why Netflix's Growth is Projected to Rise an Additional 15%
- Lancaster Resources Unveils Strategic Corporate Developments
- CrowdStrike's Growth Potential Shines Post Software Incident Recovery
- Music Licensing, Inc. Partners with SmallCapVoice for Growth
- Maximize Your Earnings: Unlocking $68,500 Yearly Dividends
- Windtree Therapeutics Updates Investors at ThinkEquity Event
- Ekso Bionics Set to Announce Major Financial Updates Soon
- Taboola Partners with National World for Enhanced Content Delivery
- Dayforce Unveils Campaign Aimed at Enhancing Work Life
- LENZ Therapeutics Enhances Near Vision with LNZ100 NDA Success
- Canadian North Resources Enhances Metal Recovery with Bio-Leaching
- Pacira BioSciences Welcomes Shawn Cross as CFO to Boost Growth
- Pyxis Tankers Set to Showcase Innovations at ThinkEquity Conference
- Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study
- Cyabra CEO Set to Share Insights at Major Conference Event
- Waltz Health and Noom Join Forces for Innovative Weight Loss Solutions
- 5E Advanced Materials Sees Operational Success and Tax Benefits
- Pyxis Tankers Set for Engaging Participation at Conference
- CACI Secures $805 Million Contract for Naval Support Services
- Boeing's New Labor Deal Signals Hope for Stability
- Pacira BioSciences Welcomes Shawn Cross as New CFO
- Stingray Launches Innovative Video Channels for BMW Drivers
- Transformative AI Credit Underwriting at Sidney Federal Credit Union
- Ekso Bionics Prepares for Q3 2024 Financial Results Release
- o9's Groundbreaking Catena-X Certification Revolutionizes Auto Data
- Windtree Therapeutics to Showcase Innovations at a Major Event
- Protara Therapeutics Advances IV Choline Chloride for Patients
- Reynolds and Reynolds Deepens Payments Partnership with Worldpay
- Immunohistochemistry Market Expected to Reach USD 5.5 Billion
- Cumulus Media Sets Date for Q3 2024 Results Conference Call
- Kantata Honors Innovative Leaders with 2024 Catalyst Awards
- Revolutionizing Metal Extraction with Bio-Leaching at Ferguson Lake
- Mainz Biomed's 2024 Financial Performance and Growth Strategy